These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32759249)

  • 1. Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study.
    Song TJ; Kim J; Han SW; Kim YD; Lee JY; Ahn SH; Lee HS; Jung YH; Lee KY
    BMJ Open; 2020 Aug; 10(8):e038031. PubMed ID: 32759249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial.
    Han SW; Kim YJ; Ahn SH; Seo WK; Yu S; Oh SH; Kim YN; Lee KY;
    Int J Stroke; 2016 Jun; 11(4):485-91. PubMed ID: 26763917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
    Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
    Han Y; Lv HH; Liu X; Dong Q; Yang XL; Li SX; Wu S; Jiang JM; Luo Z; Zhu DS; Zhang Y; Zheng Y; Guan YT; Xu JF
    CNS Neurosci Ther; 2015 Sep; 21(9):692-7. PubMed ID: 26177117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
    Wang Y; Zhao X; Lin J; Li H; Johnston SC; Lin Y; Pan Y; Liu L; Wang D; Wang C; Meng X; Xu J; Wang Y;
    JAMA; 2016 Jul; 316(1):70-8. PubMed ID: 27348249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel.
    Jeong TD; Kim SM; Kim HJ; Lee W; Kwon SU; Min WK; Kang DW; Chun S
    J Stroke Cerebrovasc Dis; 2015 Feb; 24(2):440-6. PubMed ID: 25529343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of
    Pilling LC; Türkmen D; Fullalove H; Atkins JL; Delgado J; Kuo CL; Kuchel GA; Ferrucci L; Bowden J; Masoli JAH; Melzer D
    BMJ Open; 2021 Dec; 11(12):e053905. PubMed ID: 34903548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C19 polymorphisms and clopidogrel efficacy in the secondary prevention of ischemic stroke: a retrospective observational study.
    Lin J; Mo Y; Cai D; Mao D; Fu H; Wei D
    Ann Palliat Med; 2021 Dec; 10(12):12171-12180. PubMed ID: 35016407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.
    McDonough CW; McClure LA; Mitchell BD; Gong Y; Horenstein RB; Lewis JP; Field TS; Talbert RL; Benavente OR; Johnson JA; Shuldiner AR
    J Am Heart Assoc; 2015 May; 4(6):e001652. PubMed ID: 26019129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
    Lin J; Han Z; Wang C; Yi X; Chai Z; Zhou Q; Huang R
    Eur J Clin Pharmacol; 2018 Sep; 74(9):1131-1140. PubMed ID: 29804161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G
    Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention].
    Wu Y; Zhang XX; Tian L; Jiang JJ; Xu L; Huang YL; Liu H; Li YS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):377-385. PubMed ID: 28511321
    [No Abstract]   [Full Text] [Related]  

  • 13. Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Xie X; Johnston SC; Wang A; Xu Q; Bath PM; Pan Y; Li H; Lin J; Wang Y; Zhao X; Li Z; Jiang Y; Liu L; Xu A; Jing J; Meng X; Wang Y
    JAMA Netw Open; 2023 Jun; 6(6):e2317037. PubMed ID: 37279000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
    Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA
    JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
    Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
    JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors.
    Tomek A; Matʼoška V; Frýdmanová A; Magerová H; Šrámek M; Paulasova-Schwabová J; Růžičková T; Janský P; Šarbochová I; Hadačová I; Kaplan V; Lacinová Z; Táborský L; Serebruany V
    Am J Ther; 2018; 25(2):e202-e212. PubMed ID: 29509167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
    Yi X; Zhou Q; Wang C; Lin J; Cheng W; Chi L
    J Stroke Cerebrovasc Dis; 2016 Dec; 25(12):2859-2867. PubMed ID: 27546731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
    Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
    Bhatt DL; Paré G; Eikelboom JW; Simonsen KL; Emison ES; Fox KA; Steg PG; Montalescot G; Bhakta N; Hacke W; Flather MD; Mak KH; Cacoub P; Creager MA; Berger PB; Steinhubl SR; Murugesan G; Mehta SR; Kottke-Marchant K; Lincoff AM; Topol EJ;
    Eur Heart J; 2012 Sep; 33(17):2143-50. PubMed ID: 22450429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.